Sinovac CEO Yin Responds to Controversies Surrounding CoronaVac

The transcript discusses the global disparity in vaccine distribution, focusing on the use of mRNA vaccines versus other types. It highlights the importance of vaccine safety and efficacy, noting that real-world effectiveness can differ from trial results. The conversation also touches on the challenges of achieving high vaccination rates and the tradeoffs made during emergency responses. Finally, it examines China's growing vaccine industry and its capacity to produce large quantities of vaccines.

What is a major factor affecting the willingness of people to get vaccinated?

• The cost of the vaccine

• The availability of the vaccine

• The safety and side effects of the vaccine

• The brand of the vaccine

What is the ultimate goal in managing the pandemic according to the transcript?

• Reducing the number of cases

• Distributing vaccines equally

• Achieving the highest efficacy rate

• Developing new vaccines

How does the public's knowledge of COVID-19 vaccines compare to that of flu vaccines?

• The public knows less about COVID-19 vaccines

• The public knows more about COVID-19 vaccines

• The public is not interested in either

• The public knows the same about both

What is a key priority during an emergency vaccine rollout?

• Publishing research papers

• Reducing vaccine costs

• Meeting vaccine demand

• Developing new vaccines

What does the transcript suggest about China's vaccine production capacity?

• China can produce 2 billion doses annually

• China can produce 500 million doses annually

• China can produce 1 billion doses annually

• China can produce 3 billion doses annually